Solutions to Avoid False Positives for Rituximab in Pre-Transplant Crossmatches

Rituximab (anti-CD20) is commonly used as immunotherapy against B cells, in the context of pre-transplant crossmatches, where the presence of rituximab in the tested sera with donor cells can alter their results both by flow cytometry (FCXM) as complement-dependent cytotoxicity (CDCXM) giving rise t...

Descripción completa

Detalles Bibliográficos
Autores principales: Colmenero Velazquez, Argentina, Iturrieta-Zuazo, Ignacio, Valdivieso Shephard, Juan Luis, Di Natale, Marisa, Rita, Claudia, Ballester González, Rubén, Castañer Alabau, José Luis, Nieto Gañán, Israel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551202/
https://www.ncbi.nlm.nih.gov/pubmed/32764391
http://dx.doi.org/10.3390/antib9030041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551202/
https://www.ncbi.nlm.nih.gov/pubmed/32764391
http://dx.doi.org/10.3390/antib9030041

Ejemplares similares